Colorectal cancer in inflammatory bowel diseases in St. Petersburg: results of an analytical study

Introduction. Ulcerative colitis (UC) and Crohn’s disease (CD) belong to the category of inflammatory bowel disease (IBD) and are one of the most pressing problems of gastroenterology worldwide, including due to the development of specific life-threatening complications. Chronic inflammation in the colon in IBD is the cause of the development of one of these complications - colorectal cancer, which requires disabling colectomies and is also one of the leading causes of death among IBD patients. In the Russian population of IBD patients the prevalence of dysplasia and cancer of the colon mucosa has not been previously studied in large epidemiological studies. The aim of the study was to assess the incidence of colorectal cancer in patients with IBD in St. Petersburg. Materials and methods. Within the framework of this publication, the results of three studies were compared: a single-center retrospective cohort study conducted on the basis of the city center of IBD in St. Petersburg (516 patients with IBD who admitted to this medical institution for the period 2020-2023); a multicenter epidemiological study aimed at assessing the clinical features of IBD among the population of St. Petersburg (1072 patients with IBD who admitted to 42 outpatient clinics and 6 city hospitals in 2018-2020); registry study based on the general statistical module of the regional IBD Register of St. Petersburg, operating on the basis of a regional fragment of the unified healthcare state information system (12,858 patients with IBD, data collection period: 2019-2022). Results. As a result of comparing data from three studies, the incidence of IBD-associated colorectal cancer in St. Petersburg was calculated, which was 15.7 cases per 10,000 patients with UC per year and 11.5 cases per 10,000 patients with CD per year. Compared to the population of St. Petersburg as a whole, the likelihood of developing colorectal cancer in patients with UC was 2.9 times higher, in patients with CD - 2.4 times higher. At the same time, in a single-center study, when assessing the prevalence of IBD-associated colorectal cancer, it was found that compared with other life-threatening complications of IBD, it was much less common: toxic dilatation of the intestine occurred 3 times more often, intestinal perforation occurred 20 times more often, decompensated bowel stricture occurred 21 times more often, and severe anemia requiring blood transfusion occurred 36 times more common. Also, as a result of a single-center study, it was found that for 1 case of IBD-associated dysplasia of the colon mucosa, there were 5 cases of sporadic dysplasia. Conclusion. The selection of the most effective therapy and systematic endoscopic examination of patients with IBD will significantly reduce the likelihood of developing colorectal cancer, and systematic observation of the patient with regular endoscopic monitoring of the colon with multifocal biopsy will allow timely detection of dysplasia of the colon mucosa in accordance with current clinical guidelines. It can be assumed that within the framework of cancer prevention measures in the first years of follow-up of a patient with IBD from the onset of the disease, it is advisable to give priority to the risk of developing not only IBD-associated dysplasia, but also sporadic dysplasia of the colon mucosa.

inflammatory bowel disease, Crohn’s disease, ulcerative colitis, colorectal cancer, dysplasia, epidemiology, IBD registry of St. Petersburg, complications, St. Petersburg

1. Ivashkin V.T., Shelygin Yu.A., Belousova E. A. et al. Project of clinical recommendations for the diagnosis and treatment of ulcerative colitis. Coloproctology. 2023;22(1):10-44. (in Russ.) doi: 10.33878/2073-7556-2023-22-1-10-44 (in Russ.).@@ Ивашкин В. Т., Шелыгин Ю. А., Белоусова Е. А. и соавт. Клинические рекомендации. Язвенный колит (K51), взрослые. Колопроктология. 2023;22(1):10-44. doi: 10.33878/2073-7556-2023-22-1-10-44.

2. Ivashkin V.T., Shelygin Y. A., Abdulganieva D. I. et al. Clinical recommendations for the diagnosis and treatment of Crohn’s disease in adults (project). Coloproctology. 2020;19(2):8-38. (in Russ.) doi: 10.33878/2073-7556-2020-19-2-8-38.@@ Ивашкин В. Т., Шелыгин Ю. А., Абдулганиева Д. И. и соавт. Клинические рекомендации по диагностике и лечению болезни Крона у взрослых (проект). Колопроктология. 2020;19(2):8-38. doi: 10.33878/2073-7556-2020-19-2-8-38.

3. Flynn S. Eisenstein S. Inflammatory Bowel Disease Presentation and Diagnosis. SurgClin North Am. 2019; 99(6):1051-1062. doi 10.1016/j.suc.2019.08.001.

4. Hodson R. Inflammatory bowel disease. Nature. 2016; 540(7634): S97. doi: 10.1038/540s97a.

5. Shah S.C., Itzkowitz S. H. Colorectal Cancer in Inflammatory Bowel Disease: Mechanisms and Management. Gastroenterology. 2022;162(3):715-730.e3. doi: 10.1053/j.gastro.2021.10.035.

6. Mattar M.C., Lough D., Pishvaian M. J., Charabaty A. Current management of inflammatory bowel disease and colorectal cancer. Gastrointest. Cancer Res. 2011; 4:53-61.

7. Lutgens M.W.M.D. et al. Declining risk of colorectal cancer in inflammatory bowel disease: an updated meta-analysis of population-based cohort studies. Inflamm. Bowel Dis. 2013;19:789-799.

8. Eaden J.A., Abrams K. R., Mayberry J. F. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut. 2001;48:526-535.

9. Selinger C.P. et al. Long-term follow-up reveals low incidence of colorectal cancer, but frequent need for resection, among Australian patients with inflammatory bowel disease. Clin. Gastroenterol. Hepatol. 2014;(12):644-650.

10. Bopanna S., Ananthakrishnan A. N., Kedia S. et al. Risk of colorectal cancer in Asian patients with ulcerative colitis: a systematic review and meta-analysis. Lancet Gastroenterol. Hepatol. 2017;2:269-276.

11. Choi C.H., Rutter M. D., Askari A. et al. Forty-Year Analysis of Colonoscopic Surveillance Program for Neoplasia in Ulcerative Colitis: An Updated Overview. Am J Gastroenterol. 2015;110(7):1022-1034. doi:10.1038/ajg.2015.65.

12. Bikbava G.R., Livzan M. A., Fedorin M. M. Risk factors for colorectal cancer in IBD patients. Experimental and clinical gastroenterology. 2022;205(9):140-146. (in Russ.) doi: 10.31146/1682-8658-ecg-205-9-140-146.@@ Бикбавова Г. Р., Ливзан М. А., Федорин М. М. Факторы риска колоректального рака у больных ВЗК. Экспериментальная и клиническая гастроэнтерология. 2022;205(9):140-146. doi: 10.31146/1682-8658-ecg-205-9-140-146.

13. Frick A., Khare V., Paul G. et al. Overt increase of oxidative stress and dna damage in murine and human colitis and colitis-associated neoplasia. Mol Cancer Res. 2018;16:634-642.

14. Wijnands A.M., de Jong M. E., Lutgens M. W.M.D. et al. Prognostic Factors for Advanced Colorectal Neoplasia in Inflammatory Bowel Disease: Systematic Review an Meta-analysis. Gastroenterology. 2021;160(5):1584-1598. doi:10.1053/j.gastro.2020.12.036

15. Turner D., Ricciuto A., Lewis A. et al. STRIDE-II: an update on the selecting therapeutic targets in inflammatory bowel disease (STRIDE) initiative of the international organization for the study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD. Gastroenterology. 2021;160:1570-1583.

16. Bouguen G., Levesque B. G., Feagan B. G. et al. Treat to target: a proposed new paradigm for the management of Crohn’s disease. Clin Gastroenterol Hepatol. 2015;13:1042-1050.e2.

17. Peyrin-Biroulet L., Sandborn W., Sands B. E. et al. Selecting therapeutic targets in inflammatory bowel disease (STRIDE): determining therapeutic goals for treat-to-target. Am J Gastroenterol. 2015;110:1324-1338.

18. Belousova E.A., Abdulganiyeva D. I., Alexeyeva O. P. et al. Social-demographic characteristics, current features and treatment options for inflammatory bowel diseases in Russia. The results of two multicenter studies. Almanac of Clinical Medicine. 2018;46(5):445-463. (In Russ.) doi: 10.18786/2072-0505-2018-46-5-445-463.@@ Белоусова Е. А., Абдулганиева Д. И., Алексеева О. П. и соавт. Социально-демографическая характеристика, особенности течения и варианты лечения воспалительных заболеваний кишечника в России. Результаты двух многоцентровых исследований. Альманах клинической медицины. 2018;46(5):445-463. doi: 10.18786/2072-0505-2018-46-5-445-463.

19. Knyazev O.V., Belousova E. A., Abdulganieva D. I. et al. Real practice of drug therapy of moderate and severe forms of inflammatory bowel diseases in Russia, the Republic of Belarus and the Republic of Kazakhstan.Interim results of the INTENT study. Almanac of Clinical Medicine. 2021;49(7):443-454. (in Russ.) doi: 10.18786/2072-0505-2021-49-061.@@ Князев О. В., Белоусова Е. А., Абдулганиева Д. И. и соавт. Реальная практика лекарственной терапии среднетяжелых и тяжелых форм воспалительных заболеваний кишечника в России, Республике Беларусь и Республике Казахстан. Промежуточные результаты исследования INTENT. Альманах клинической медицины. 2021;49(7):443-454. doi: 10.18786/2072-0505-2021-49-061.

20. Belousova E.A., Shelygin Yu.A., Achkasov S. I., et al. Clinical and demographic characteristics and treatment approaches in patients with inflammatory bowel diseases (Crohn’s disease, ulcerative colitis) in the Russian Federation. The first results of the analysis of the National Register. Coloproctology. 2023;22(1):65-82. (in Russ.) doi: 0.33878/2073-7556-2023-22-1-65-82.@@ Белоусова Е. А., Шелыгин Ю. А., Ачкасов С. И., и соавт. Клинико-демографические характеристики и лечебные подходы у пациентов с воспалительными заболеваниями кишечника (болезнь Крона, язвенный колит) в РФ. Первые результаты анализа Национального Регистра. Колопроктология. 2023;22(1):65-82. doi: 0.33878/2073-7556-2023-22-1-65-82.

21. Uspenskiy Y.P., Ivanov S. V., Fominikh Yu.A., Galagudza M. M. Features of inflammatory bowel diseases in St. Petersburg and peculiarities of basic therapy in the regional healthcare system: cross-sectional study results. Experimental and Clinical Gastroenterology. 2021;1(6):29-39. (In Russ.) doi 10.31146/1682-8658-ecg-190-6-29-39.@@ Успенский Ю. П., Иванов С. В., Фоминых Ю. А., Галагудза М. М. Клиническая характеристика воспалительных заболеваний кишечника в Санкт-Петербурге и особенности использования базисной терапии в системе городского здравоохранения: результаты одномоментного эпидемиологического исследования. Экспериментальная и клиническая гастроэнтерология. 2021;190(6):29-39. doi: 10.31146/1682-8658-ecg-190-6-29-39.